{
    "clinical_study": {
        "@rank": "26772", 
        "arm_group": {
            "arm_group_label": "Autologous Muscle Progenitor Cells", 
            "arm_group_type": "Experimental", 
            "description": "Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region"
        }, 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety of muscle progenitor cells (MPCs) for the\n      treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra)."
        }, 
        "brief_title": "Muscle Progenitor Cell Therapy for Urinary Incontinence", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Incontinence", 
        "condition_browse": {
            "mesh_term": "Urinary Incontinence"
        }, 
        "detailed_description": {
            "textblock": "Eligible subjects with a diagnosis of urinary incontinence who give consent to take part\n      will undergo a biopsy of the muscle from the inner thigh under anesthesia. The muscle sample\n      will be cultured and expanded for approximately 6 weeks. The product, composed of\n      autologous, ex vivo-expanded muscle progenitor cells (MPCs) in suspension, will be delivered\n      via targeted injection into the bladder neck sphincter region using either an endoscopic\n      needle via a cystoscope or periurethral injection under ultrasound guidance.  All subjects\n      will be followed at 1 week, 6 weeks, 3 months, 6 months and 12 months post-injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult female patients who are not pregnant or lactating/breast-feeding and must be\n             either not sexually active, surgically sterilized, or must be practicing an effective\n             method of birth control as determined by the investigator (e.g., oral contraceptives,\n             double barrier methods, hormonal injectable or implanted contraceptives, tubal\n             ligation, or partner with vasectomy)\n\n          -  Patients between the ages of 18 and 75 years\n\n          -  Patients with positive diagnosis of urinary incontinence due to sphincter\n             insufficiency caused by acquired (e.g., stress urinary incontinence) and/or\n             congenital (bilateral ectopic ureters with incompetent bladder neck; or female\n             epispadias with or without bladder exstrophy) conditions.\n\n          -  Patients with cystometric capacity of bladder > 100 ml\n\n          -  Patients with normal renal function\n\n          -  Patients with a history of primary incontinence\n\n        Exclusion Criteria:\n\n          -  Patients with a history of hypercontractile bladder, non-compliant bladder,\n             hydronephrosis or neurogenic bladder\n\n          -  Patients with an active urinary tract infection as evidenced by positive urine\n             culture\n\n          -  Patients who are taking medication that affect urination (e.g. medically necessary,\n             stable drugs) such as prescription drugs, over-the-counter drugs, or dietary\n             supplements, including herbal supplements and those taken with teas\n\n          -  Patients requiring concomitant use of or treatment with immunosuppressive agents\n\n          -  Patients with a history of systemic conditions, including but not limited to HIV,\n             diabetes and chronic liver disease (including Hepatitis B or C), that the\n             Investigator believes may jeopardize the safety of the patient to participate in the\n             study\n\n          -  Patients with evidence or diagnosis of any primary muscle disease or coagulation\n             disorder (including concomitant anti-coagulation therapy at enrollment)\n\n          -  Patients who have been treated with any other investigational drug or participated in\n             any investigational study within 30 days prior to enrollment in this study\n\n          -  Patients with urinary incontinence other than the categories being investigated\n\n          -  Patients with significant (>grade 2) pelvic organ prolapse (e.g., cystocele,\n             rectocele)\n\n          -  Patients with vaginal prolapse beyond introitus\n\n          -  Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease)\n\n          -  Patients with abnormal bladder capacity (i.e., less than 100 cc)\n\n          -  Patients with abnormal urologic conditions, including post-void residual, urethral\n             stricture and bladder neck contracture, spastic bladder, vesicoureteral reflux,\n             bladder stones, bladder tumors, hydronephrosis, other renal impairment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953315", 
            "org_study_id": "00023616"
        }, 
        "intervention": {
            "arm_group_label": "Autologous Muscle Progenitor Cells", 
            "description": "Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region", 
            "intervention_name": "Autologous Muscle Progenitor Cells", 
            "intervention_type": "Biological", 
            "other_name": "MPCs"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "urinary incontinence, muscle progenitor cells, MPCs", 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mday@wakehealth.edu", 
                    "last_name": "Mary-Clare Day, RN, BSN", 
                    "phone": "336-713-1343"
                }, 
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27103"
                    }, 
                    "name": "Wake Forest Urology Clinic"
                }, 
                "investigator": {
                    "last_name": "Gopal Badlani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "James Yoo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157"
                    }, 
                    "name": "Wake Forest Institute for Regenerative Medicine (WFIRM)"
                }, 
                "investigator": {
                    "last_name": "James Yoo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Pilot Safety and Feasibility Study of Muscle Progenitor Cell (MPC) Therapy for Urinary Incontinence", 
        "overall_contact": {
            "email": "mday@wakehealth.edu", 
            "last_name": "Mary-Clare Day, RN, BSN", 
            "phone": "336-713-1343"
        }, 
        "overall_contact_backup": {
            "email": "gbadlani@wakehealth.edu", 
            "last_name": "Gopal Badlani, MD"
        }, 
        "overall_official": {
            "affiliation": "Wake Forest School of Medicine, Dept. of Urology", 
            "last_name": "Gopal Badlani, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the subject/biopsy/treatment site will be monitored for signs of bleeding, infection, continued pain, prolonged hospitalization", 
            "measure": "Incidence of treatment-related serious adverse events and the incidence of protocol defined treatment or procedure related adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953315"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wake Forest School of Medicine", 
            "investigator_full_name": "Gopal Badlani, MD", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will undergo 1 hour and 24 hour pad tests (pads are weighed)at baseline which are compared to the tests post-injection treatment", 
                "measure": "change in Incontinence Assessment by pad test", 
                "safety_issue": "No", 
                "time_frame": "baseline, 3, 6, and 12 months post-injection"
            }, 
            {
                "description": "through Voiding diaries, the number of incontinence episodes and pads used per day are compared to baseline", 
                "measure": "change in Number of incontinence episodes and pads used per day", 
                "safety_issue": "No", 
                "time_frame": "baseline, 3, 6 and 12 months post-injection treatment"
            }, 
            {
                "description": "subjects will complete the Urinary Incontinence and Quality of Life questionnaires and the baseline results will be compared to the 3, 6 and 12 months post injection results.", 
                "measure": "change in Urogenital distress and quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline, 3, 6 and 12 months post-injection treatment"
            }
        ], 
        "source": "Wake Forest School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gopal Badlani, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}